CA SB912

Requires health care service plans and health insurance policies issued on or after July 1, 2023 to cover biomarker testing (including whole genome sequencing) for diagnosis, treatment, management, or monitoring of disease or condition if supported by medical and scientific evidence.

Defines "medical and scientific evidence" as FDA-approved tests, national or local Medicare coverage determinations, or nationally recognized clinical practice guidelines and consensus statements.

Specifies coverage does not apply to screening purposes unless otherwise required by law and requires testing be provided in manner limiting multiple biopsies or biospecimen samples.

Expands Medi-Cal program to include biomarker testing as covered benefit by July 1, 2023, subject to utilization controls and federal financial participation approval.

Makes biomarker testing subject to state and federal grievance and appeal processes; exempts certain insurance types (vision-only, dental-only, accident-only, Medicare supplement, long-term care, and disability income insurance).